Under physiological conditions, O‐GlcNAcylation levels are maintained by a balanced ‘write–erase’ cycle; in pathological states such as cancer, overexpression of OGT or loss of OGA activity disrupts this homeostasis, driving malignancy through reprogramming of metabolic, epigenetic and signalling networks. The gene discussed is OGA; the disease is cancer.